-
1
-
-
0029150795
-
Proteolytic remodelling of extracellular matrix
-
728-735.
-
Birkedal-Hansen H: Proteolytic remodelling of extracellular matrix. Curr Opin Cell Biol (1995) 7:728-735.
-
(1995)
Curr Opin Cell Biol
, vol.7
-
-
Birkedal-Hansen, H.1
-
2
-
-
0025847582
-
Matrix metalloproteinases and their inhibitors in connective tissue remodeling
-
2145-2154.
-
Woessner JR Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 5:2145-2154.
-
(1991)
FASEB J
, vol.5
-
-
Woessner, J.R.1
-
3
-
-
0029383456
-
Matrix metalloproteinases and their inhibitors
-
55-60.
-
Murphy G: Matrix metalloproteinases and their inhibitors. Ada Orthop Scant/ Suppl (1995) 266:55-60.
-
(1995)
Ada Orthop Scant/ Suppl
, vol.266
-
-
Murphy, G.1
-
4
-
-
0032427413
-
Metalloproteinases and tissue inhibitors of metalloproteinases
-
Ishigaki S, Tominaga T: 113-124.
-
Toi M, Ishigaki S, Tominaga T: Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat (1998) 52:113-124.
-
(1998)
Breast Cancer Res Treat
, vol.52
-
-
Toi, M.1
-
5
-
-
0034013953
-
Matrix metalloproteinase inhibitors in the treatment of arthritis
-
Rowan AD, Cawston TE: 16-25. An excellent and up-to-date review of the role of MMPs and utility ofMMPIs in the treatment of arthritis.
-
Clark IM, Rowan AD, Cawston TE: Matrix metalloproteinase inhibitors in the treatment of arthritis. Curr Opin Antiinflamm Immunomod Invest Drugs (2000) 2:16-25. An excellent and up-to-date review of the role of MMPs and utility ofMMPIs in the treatment of arthritis.
-
(2000)
Curr Opin Antiinflamm Immunomod Invest Drugs
, vol.2
-
-
Clark, I.M.1
-
6
-
-
0031460236
-
Matrix metalloproteinase inhibitor drugs
-
205-230.
-
Levy DE, Ezrin AM: Matrix metalloproteinase inhibitor drugs. Emerging Drugs (1997) 2:205-230.
-
(1997)
Emerging Drugs
, vol.2
-
-
Levy, D.E.1
Ezrin, A.M.2
-
7
-
-
0028483534
-
Regulation of tumor necrosis factor processing by a metalloproteinase inhibitor
-
Becherer JD, Bast RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nichols J, Pryzwansky KM, Schoenen F, Sekul L, Truesdale A, Verghese M, Warner J, Ways JP: 558-561.
-
McGeehan GM, Becherer JD, Bast RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nichols J, Pryzwansky KM, Schoenen F, Sekul L, Truesdale A, Verghese M, Warner J, Ways JP: Regulation of tumor necrosis factor processing by a metalloproteinase inhibitor. Nature (1994) 370:558-561.
-
(1994)
Nature
, vol.370
-
-
McGeehan, G.M.1
-
8
-
-
0028485654
-
Processing of tumor necrosis factor-a precursor by metalloproteinases
-
Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Wooley K: 555-557.
-
Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Wooley K: Processing of tumor necrosis factor-a precursor by metalloproteinases. Nature (1994) 370:555-557.
-
(1994)
Nature
, vol.370
-
-
Gearing, A.J.1
-
9
-
-
8044257704
-
A metalloproteinase disintegrin that releases tumor-necrosis factor from cells
-
Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: 729-733.
-
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumor-necrosis factor from cells. Nature (1997) 385:729-733.
-
(1997)
Nature
, vol.385
-
-
Black, R.A.1
-
10
-
-
8044250278
-
Cloning of a disintegrin metalloproteinase that processes precursor tumor necrosis factor-a
-
Jin S-LC, Milla ME, Burkhart W, Carter HL, Chen W- J, Clay WC, Didsbury JR, Hassler D, Huffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, Mageehan G, Mitchell J, Moyer M, Panel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su J-L, Wamer J, Willard D, Becherer JD: 733-736.
-
Moss ML, Jin S-LC, Milla ME, Burkhart W, Carter HL, Chen W- J, Clay WC, Didsbury JR, Hassler D, Huffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, Mageehan G, Mitchell J, Moyer M, Panel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su J-L, Wamer J, Willard D, Becherer JD: Cloning of a disintegrin metalloproteinase that processes precursor tumor necrosis factor-a. Nature (1997) 385:733-736.
-
(1997)
Nature
, vol.385
-
-
Moss, M.L.1
-
11
-
-
0031698581
-
ADAMs: Focus on the protease domain
-
White JM: 654-659. Excellent review highlighting the role of members of this emerging gene family in health and disease.
-
Black RA, White JM: ADAMs: Focus on the protease domain. Curr Opin Cell Biol (1998) 10:654-659. Excellent review highlighting the role of members of this emerging gene family in health and disease.
-
(1998)
Curr Opin Cell Biol
, vol.10
-
-
Black, R.A.1
-
12
-
-
0032961923
-
The therapeutic potential of small molecule TACE inhibitors
-
Zask A: 383-392. The first review in the MMPI area with a focus entirely on TACE.
-
Nelson FC, Zask A: The therapeutic potential of small molecule TACE inhibitors. Exp Opin Invest Drugs (1999) 8:383-392. The first review in the MMPI area with a focus entirely on TACE.
-
(1999)
Exp Opin Invest Drugs
, vol.8
-
-
Nelson, F.C.1
-
13
-
-
0031032891
-
Membrane protein secretases
-
Karran EH, Turner AJ: 265-279.
-
Hooper NM, Karran EH, Turner AJ: Membrane protein secretases. Biochem J(1997) 321:265-279.
-
(1997)
Biochem J
, vol.321
-
-
Hooper, N.M.1
-
14
-
-
0031148967
-
A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells
-
Morand V, Millet S, Bruneau JM, Bhatnagar N, Chouaib S, Roman-Roman S: 340-346.
-
Gallea-Robache S, Morand V, Millet S, Bruneau JM, Bhatnagar N, Chouaib S, Roman-Roman S: A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors In human monocytic cells. Cytokine (1997) 9:340-346.
-
(1997)
Cytokine
, vol.9
-
-
Gallea-Robache, S.1
-
15
-
-
0032170034
-
Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (T1MP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-a receptors in a human colon adenocarcinoma (Colo 205) cell line
-
Wallace TL, Kubicek MF, Petzold GL, Mitchell MA, Hendges SX, Wilks JW: 4001-4007.
-
Lombard MA, Wallace TL, Kubicek MF, Petzold GL, Mitchell MA, Hendges SX, Wilks JW: Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (T1MP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-a receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res (1998) 58:4001-4007.
-
(1998)
Cancer Res
, vol.58
-
-
Lombard, M.A.1
-
16
-
-
0031776982
-
Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
-
Toni J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ: 2150-2156. Perspective on the issues surrounding the utility of first generation MMPIs in the clinical setting.
-
Wojtowicz-Praga S, Toni J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Onco/(1998) 16:2150-2156. Perspective on the issues surrounding the utility of first generation MMPIs in the clinical setting.
-
(1998)
J Clin Onco/
, vol.16
-
-
Wojtowicz-Praga, S.1
-
17
-
-
33749968324
-
What is the appropriate selectivity for development of MMP inhibitors for therapeutic use?
-
New London, NH, USA
-
Bird J: What is the appropriate selectivity for development of MMP inhibitors for therapeutic use? Gordon Research Conference: Matrix Metalloproteinases. New London, NH, USA (1999).
-
(1999)
Gordon Research Conference: Matrix Metalloproteinases.
-
-
Bird, J.1
-
18
-
-
0028838862
-
Structure determination and analysis of human nuetrophil collagenase complexed with a hydroxamate inhibitor
-
Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H, Bode W: 14012-14020.
-
Grams F, Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H, Bode W: Structure determination and analysis of human nuetrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry (1995) 34:14012-14020.
-
(1995)
Biochemistry
, vol.34
-
-
Grams, F.1
-
20
-
-
0030964706
-
Design and synthesis of the cartilage protective agent (CPA, Ro-323555)
-
Borkakoti N, Bottomley KM, Cooper Ml, Eatherton AJ, Kilford IR, Broadhurst MJ, Nixon JS, Brown PA, Lewis EJ, Lawton G, Sutton BM, Ballantyne N, Johnson WH: 2299-2302.
-
Malsher PJ, Borkakoti N, Bottomley KM, Cooper Ml, Eatherton AJ, Kilford IR, Broadhurst MJ, Nixon JS, Brown PA, Lewis EJ, Lawton G, Sutton BM, Ballantyne N, Johnson WH: Design and synthesis of the cartilage protective agent (CPA, Ro-323555). Bioorg Med Chem Lett (1997) 7:2299-2302.
-
(1997)
Bioorg Med Chem Lett
, vol.7
-
-
Malsher, P.J.1
-
21
-
-
0031654554
-
Ro-32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis
-
Lewis EJ, Wilson KL, Greenham AK, Bottomley KM: 1639-1644.
-
Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley KM: Ro-32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum (1998) 41:1639-1644.
-
(1998)
Arthritis Rheum
, vol.41
-
-
Brewster, M.1
-
22
-
-
0030728087
-
Cartilage protective agent (CPA) Ro-32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis
-
Aiken M, Durston S, Harris S, McClelland GR, Sharp S: 49-55.
-
Wood ND, Aiken M, Durston S, Harris S, McClelland GR, Sharp S: Cartilage protective agent (CPA) Ro-32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. Agents Actions Suppl (1997) 49:49-55.
-
(1997)
Agents Actions Suppl
, vol.49
-
-
Wood, N.D.1
-
24
-
-
8244221001
-
Ro-32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo
-
Bishop J, Bottomley KM, Bradshaw D, Brewsler M, Broadhurst MJ, Brown PA, Budd JM, Elliott L, Greenham AK, Johnson WH, Nixon JS, Rose F, Sutton B, Wilson K: 540-546.
-
Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewsler M, Broadhurst MJ, Brown PA, Budd JM, Elliott L, Greenham AK, Johnson WH, Nixon JS, Rose F, Sutton B, Wilson K: Ro-32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown In vitro and In vivo. Br J Pharmacol (1997)121:540-546.
-
(1997)
Br J Pharmacol
, vol.121
-
-
Lewis, E.J.1
-
25
-
-
0001592085
-
D1927 and D2163: Novel mercaptoamide inhibitors of matrix metalloproteinases
-
Bird J, Bannister R, Bhogal R, Manallack DT, Watson RW, Owen DA, Montana J, Henshilwood J, Jackson RC: 193-221. A comprehensive overview of the discovery and development of mercaptoamide based MMPIs.
-
Baxter AD, Bird J, Bannister R, Bhogal R, Manallack DT, Watson RW, Owen DA, Montana J, Henshilwood J, Jackson RC: D1927 and D2163: Novel mercaptoamide inhibitors of matrix metalloproteinases. In: Cancer Drug Discovery and Development: Matrix Metalloproteinase Inhibitors in Cancer Therapy. Clendeninn NJ, Appell K (Eds), Humana Press Inc, Totowa, NJ, USA (2000) 8:193-221. A comprehensive overview of the discovery and development of mercaptoamide based MMPIs.
-
(2000)
: Cancer Drug Discovery and Development: Matrix Metalloproteinase Inhibitors in Cancer Therapy. Clendeninn NJ, Appell K (Eds), Humana Press Inc, Totowa, NJ, USA
, vol.8
-
-
Baxter, A.D.1
-
26
-
-
33749954070
-
Activities of a synthetic matrix metalloproteinase inhibitor (MMPI), BMS-275291, in models of angiogenesis and tumor metastasis. 97s/ AACR Annual Meeting
-
Jure-Kunkel M, Gao J, Smith D, Talbott R, Henderson A, Kukral D, Lewin A, Jeyaseelan R, Cardenas V, Gupta E, Huang M, Bannister R, Trail PA: 3122.
-
Naglich JG, Jure-Kunkel M, Gao J, Smith D, Talbott R, Henderson A, Kukral D, Lewin A, Jeyaseelan R, Cardenas V, Gupta E, Huang M, Bannister R, Trail PA: Activities of a synthetic matrix metalloproteinase inhibitor (MMPI), BMS-275291, in models of angiogenesis and tumor metastasis. 97s/ AACR Annual Meeting. April 1-5, San Francisco, CA, USA. Proc Amer Assoc Cancer Res (2000) 41:3122.
-
(2000)
April 1-5, San Francisco, CA, USA. Proc Amer Assoc Cancer Res
, vol.41
-
-
Naglich, J.G.1
-
27
-
-
15144353166
-
Inhibition of stromelysin-1 by Pl'-blphenylylethyl carboxyalkyl dipeptides
-
Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, Kopka IE, Lanza TJ, Levorse DA, MacCoss M, Owens KA, Ponpipom MM, Simeone JP, Harrison RK, Niedzwiecki L, Becker JW, Marcy AI, Axel MG, Christen AJ, McDonnell J, Moore VL, Olszewski JM, Saphos C, Visco DM, Shen F, Colletti A, Krieter PA, Hagmann WK: 1026-1040.
-
Esser CK, Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, Kopka IE, Lanza TJ, Levorse DA, MacCoss M, Owens KA, Ponpipom MM, Simeone JP, Harrison RK, Niedzwiecki L, Becker JW, Marcy AI, Axel MG, Christen AJ, McDonnell J, Moore VL, Olszewski JM, Saphos C, Visco DM, Shen F, Colletti A, Krieter PA, Hagmann WK: Inhibition of stromelysin-1 by Pl'-blphenylylethyl carboxyalkyl dipeptides. JMed Chem (1997) 40:1026-1040.
-
(1997)
JMed Chem
, vol.40
-
-
Esser, C.K.1
-
28
-
-
0028828048
-
Matrix metalloproteinase inhibitors: Current status
-
Millican TA, Porter JR: 743-762.
-
Morphy JR, Millican TA, Porter JR: Matrix metalloproteinase inhibitors: Current status. CurrMed Chem (1995) 2:743-762.
-
(1995)
CurrMed Chem
, vol.2
-
-
Morphy, J.R.1
-
29
-
-
0002023426
-
Recent advances in matrix metalloproteinase inhibitor research
-
Davidson AH, Drummond AH, Huxley P, Whittaker M: 16-26.
-
Beckett RP, Davidson AH, Drummond AH, Huxley P, Whittaker M: Recent advances in matrix metalloproteinase inhibitor research. Drug Disc Today (1996) 1:16-26.
-
(1996)
Drug Disc Today
, vol.1
-
-
Beckett, R.P.1
-
30
-
-
0030994326
-
Emerging therapeutic advances for the development of second generation matrix metalloproteinase inhibitors
-
Thomas MA, Bocan PA, Boxer PA, Peterson JT, Schrier D: 45-58.
-
White AD, Thomas MA, Bocan PA, Boxer PA, Peterson JT, Schrier D: Emerging therapeutic advances for the development of second generation matrix metalloproteinase inhibitors. CurrPharm Design (1997) 3:45-58.
-
(1997)
CurrPharm Design
, vol.3
-
-
White, A.D.1
-
31
-
-
0031906807
-
Matrix metalloproteinase inhibitors 1998
-
Whittaker M: 259-282.
-
Beckett RP, Whittaker M: Matrix metalloproteinase inhibitors 1998. Exp Opin Ther Pat (1998) 8:259-282.
-
(1998)
Exp Opin Ther Pat
, vol.8
-
-
Beckett, R.P.1
-
32
-
-
0032758392
-
Recent advances in matrix metalloproteinase inhibitors research
-
Curtin ML: 787-819. The most up-to-date and comprehensive review of activities in the highly competitive arena of MMPIs.
-
Michaelides MR, Curtin ML: Recent advances in matrix metalloproteinase inhibitors research. Curr Pharm Design (1999)5:787-819. The most up-to-date and comprehensive review of activities in the highly competitive arena of MMPIs.
-
(1999)
Curr Pharm Design
, vol.5
-
-
Michaelides, M.R.1
-
33
-
-
15644374838
-
Discovery of CGS-27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits
-
Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, Justice MR, Zhu L, Hu S, Melton RA, Fryer L, Goldberg RL, Doughty JR, Spirito S, Blancuzzi V, Wilson D, O'Byme EM, Ganu V, Parker DT: 2525-2532.
-
MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, Justice MR, Zhu L, Hu S, Melton RA, Fryer L, Goldberg RL, Doughty JR, Spirito S, Blancuzzi V, Wilson D, O'Byme EM, Ganu V, Parker DT: Discovery of CGS-27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem (1997) 40:2525-2532.
-
(1997)
J Med Chem
, vol.40
-
-
MacPherson, L.J.1
-
34
-
-
0032837028
-
Broad antitumor and antiangiogenic activities of AG-3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
-
Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K: 236-270.
-
Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K: Broad antitumor and antiangiogenic activities of AG-3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NYAcad Sei (1999) 878:236-270.
-
(1999)
Ann NYAcad Sei
, vol.878
-
-
Shalinsky, D.R.1
-
35
-
-
0033552866
-
Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases
-
McDow KL, Dunham NG, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE: 87-94. Excellent structural study of a novel class of MMPIs highlighting the critical nature of certain protein inhibitor interactions allowing a better understanding of new inhibitor templates.
-
Pikul S, McDow KL, Dunham NG, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE: Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. JMed Chem (1999) 42:87-94. Excellent structural study of a novel class of MMPIs highlighting the critical nature of certain protein inhibitor interactions allowing a better understanding of new inhibitor templates.
-
(1999)
JMed Chem
, vol.42
-
-
Pikul, S.1
-
36
-
-
33749952714
-
Activity of matrix metalloproteinase inhibitor (MMPI) in models of inflammation
-
Bhogal R, Baxter A, Willis R, Owen DA
-
Bird J, Bhogal R, Baxter A, Willis R, Owen DA: Activity of matrix metalloproteinase inhibitor (MMPI) in models of inflammation. Inflammation '99. Paris, France (1999).
-
(1999)
Inflammation '99. Paris, France
-
-
Bird, J.1
-
37
-
-
0032491208
-
Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, non-peptidic inhibitor
-
Zhang X, Melton R, Ganu V, Gonnella NC: 14048-14056.
-
Li Y-C, Zhang X, Melton R, Ganu V, Gonnella NC: Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, non-peptidic inhibitor. Biochemistry (1998)37:14048-14056.
-
(1998)
Biochemistry
, vol.37
-
-
Li, Y.-C.1
-
38
-
-
33749943775
-
RS-130830 inhibits cartilage degradation in vitro and in a rabbit model of osteoarthritis
-
Haller J, De Lustro B, Caufield J: 20.
-
Lollini L, Haller J, De Lustro B, Caufield J: RS-130830 inhibits cartilage degradation in vitro and in a rabbit model of osteoarthritis. Inhibition of Matrix Metalloproteinases: Therapeutic Applications. October 21-24, Tampa, FL, USA (1998):20.
-
(1998)
Inhibition of Matrix Metalloproteinases: Therapeutic Applications. October 21-24, Tampa, FL, USA
-
-
Lollini, L.1
-
39
-
-
33749974630
-
-
Welch AR, Carr S, Luong C, Broka C, Hendricks RT, Campbell JA, Walker KA, Martin R, Van Wart H, Browner MF: 13 reveal the structural basis for selectivity of collagenase inhibitors.
-
Lovejoy B, Welch AR, Carr S, Luong C, Broka C, Hendricks RT, Campbell JA, Walker KA, Martin R, Van Wart H, Browner MF: Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors.
-
Crystal Structures of MMP
, vol.1
-
-
Lovejoy, B.1
-
41
-
-
0031189711
-
Molecular recognition of protein-ligand complexes: Applications to drug design
-
Bender SL: 1359-1472. Excellent overview of the role of structure-based drug design in drug discovery.
-
Babine RE, Bender SL: Molecular recognition of protein-ligand complexes: Applications to drug design. Chem Rev (1997)97:1359-1472. Excellent overview of the role of structure-based drug design in drug discovery.
-
(1997)
Chem Rev
, vol.97
-
-
Babine, R.E.1
-
42
-
-
14444285039
-
Susceptibility of stromelysin-1 deficient mice to collagen induced arthritis and cartilage destruction
-
Hutchinson NI, Chartrain NA, Forsyth AJ, McDonnell J, Singer II, Bayne EK, Flanagan J, Kawka D, Shen CF, Stevens K, Chen H, Trumbauer M, Visco DM: 110-121. Important publication highlighting the dangers of designing truly selective inhibitors ofMMPs.
-
Mudgett JS, Hutchinson NI, Chartrain NA, Forsyth AJ, McDonnell J, Singer II, Bayne EK, Flanagan J, Kawka D, Shen CF, Stevens K, Chen H, Trumbauer M, Visco DM: Susceptibility of stromelysin-1 deficient mice to collagen induced arthritis and cartilage destruction. Arthritis Rheum (1998) 41:110-121. Important publication highlighting the dangers of designing truly selective inhibitors ofMMPs.
-
(1998)
Arthritis Rheum
, vol.41
-
-
Mudgett, J.S.1
-
43
-
-
0032997033
-
BAY-12-9566
-
Graul A, Silvestre J, Castaner J: 16-21.
-
Sorbera LA, Graul A, Silvestre J, Castaner J: BAY-12-9566. Drugs Future (1999) 24:16-21.
-
(1999)
Drugs Future
, vol.24
-
-
Sorbera, L.A.1
-
44
-
-
33749929627
-
ABT-770: A novel, selective gelatinase a inhibitor with antitumor activity in pre-clinfcal models of tumor growth
-
Albert DH, Magoc T, Tapang P, Marcotte P, Elmore l, Glaser K, Pease L, Li J, Leal J, Michaelides M, Curtin M, Holms J, Davidsen SK
-
Morgan DW, Albert DH, Magoc T, Tapang P, Marcotte P, Elmore l, Glaser K, Pease L, Li J, Leal J, Michaelides M, Curtin M, Holms J, Davidsen SK: ABT-770: A novel, selective gelatinase A inhibitor with antitumor activity in pre-clinfcal models of tumor growth. AACR-NCI-EORTC International Conference. Washington DC, USA (1999):764. Introduction to a novel series ofMMPIs with refined selectivity and excellent activity in animal models of cancer.
-
(1999)
AACR-NCI-EORTC International Conference. Washington DC, USA
, vol.764
-
-
Morgan, D.W.1
-
45
-
-
0033529047
-
Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors
-
Mitchell MA, Hendges SK, Belonga KL, Skaletzky LL, Stelzer LS, Undberg TJ, Fritzen EL, Schostarez HJ, O'Sullivan TJ, Maggiora LL, Stuchly CW, Laborde AL, Kubicek MF, Poorman RA, Beck JM, Miller HR, Petzold GL, Scott PS, Truesdell SE, Wallace TL, Wilks JW, Rsher C, Goodman LV, Kaytes PS, Ledbetter SR, Powers EA, Vogeli G, Mott JE, Trepod CM, Staples DJ, Baldwin ET, Finzel BC: 1525-1536. Excellent review of SAR in a series of compounds that presents not only a novel zinc binding group but also an unusual mode of binding in the active site ofMMPs.
-
Jacobsen EJ, Mitchell MA, Hendges SK, Belonga KL, Skaletzky LL, Stelzer LS, Undberg TJ, Fritzen EL, Schostarez HJ, O'Sullivan TJ, Maggiora LL, Stuchly CW, Laborde AL, Kubicek MF, Poorman RA, Beck JM, Miller HR, Petzold GL, Scott PS, Truesdell SE, Wallace TL, Wilks JW, Rsher C, Goodman LV, Kaytes PS, Ledbetter SR, Powers EA, Vogeli G, Mott JE, Trepod CM, Staples DJ, Baldwin ET, Finzel BC: Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors. JMed Chem (1999) 42:1525-1536. Excellent review of SAR in a series of compounds that presents not only a novel zinc binding group but also an unusual mode of binding in the active site ofMMPs.
-
(1999)
JMed Chem
, vol.42
-
-
Jacobsen, E.J.1
-
46
-
-
0033524009
-
Affinity and selectivity of matrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins
-
Schwab W: 4506-4523.
-
Matter H, Schwab W: Affinity and selectivity of matrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins. JMed Chem (1999) 42:4506-4523.
-
(1999)
JMed Chem
, vol.42
-
-
Matter, H.1
-
47
-
-
16944365890
-
Discovery of potent non-peptide inhibitors of stromelysin using SAR by NMR
-
Nettesheim DG, Olejniczak ET, Shuker SB, Meadows RP, Steinman DH, Carrera GM, Marcotte PA, Severin J, Walter K, Smith H, Gubbins E, Simmer R, Holzman TF, Morgan DW, Davidsen SK, Summers JB, Fesik SW: 5818-5827.
-
Sheppard HG, Nettesheim DG, Olejniczak ET, Shuker SB, Meadows RP, Steinman DH, Carrera GM, Marcotte PA, Severin J, Walter K, Smith H, Gubbins E, Simmer R, Holzman TF, Morgan DW, Davidsen SK, Summers JB, Fesik SW: Discovery of potent non-peptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc (1997) 119:5818-5827.
-
(1997)
J Am Chem Soc
, vol.119
-
-
Sheppard, H.G.1
-
48
-
-
0030829408
-
Stromelysin inhibitors designed from weakly bound fragments: Effects of linking and cooperativity
-
Hajduck PJ, Marcotte PA, Nettesheim DG, Meadows RP, Edalji R, Holzman TF, Fesik SW: 5828-5832. Two consecutive publications highlighting a novel approach to the design of non-substrate-based MMPIs.
-
Olejniczak ET, Hajduck PJ, Marcotte PA, Nettesheim DG, Meadows RP, Edalji R, Holzman TF, Fesik SW: Stromelysin inhibitors designed from weakly bound fragments: Effects of linking and cooperativity. J Am Chem Soc (1997) 119:5828-5832. Two consecutive publications highlighting a novel approach to the design of non-substrate-based MMPIs.
-
(1997)
J Am Chem Soc
, vol.119
-
-
Olejniczak, E.T.1
-
49
-
-
34249772251
-
Matrix metalloproteinases: Structure-based drug discovery targets
-
343-351.
-
Browner MF: Matrix metalloproteinases: Structure-based drug discovery targets. Perspect Drug Disc Des (1994) 2:343-351.
-
(1994)
Perspect Drug Disc Des
, vol.2
-
-
Browner, M.F.1
-
50
-
-
33749943196
-
Structural characteristics of the matrix metalloproteinases
-
Bradshaw D, Nixon JS (Eds), Berkhauser Verlag, Basel, Switzerland 1-16.
-
Borkakoti N: Structural characteristics of the matrix metalloproteinases. In: Metalloproteinases as Targets for Anti-inflammatory Drugs. Bottomley KM, Bradshaw D, Nixon JS (Eds), Berkhauser Verlag, Basel, Switzerland (1999):1-16.
-
(1999)
In: Metalloproteinases as Targets for Anti-inflammatory Drugs. Bottomley KM
-
-
Borkakoti, N.1
-
51
-
-
0344019404
-
Crystal structure of the catalytic domain of human tumor necrosis factor-a-converting enzyme
-
Fernandez-Catalan C, Huber R, Bourenkov GP, Bartunik H, Ellestad GA, Reddy P, Wolfson MF, Rauch CT, Castner BJ, Davis R, Clarke HR, Petersen M, Fitzner JN, Cerretti DP, March CJ, Paxton RJ, Black RA, Bode W: 3408-3412. The first crystal structure of an ADAM gene family member. There will be considerable use of structure-based studies in the design of inhibitors of ADAM and ADAM-TS gene family members.
-
Maskos K, Fernandez-Catalan C, Huber R, Bourenkov GP, Bartunik H, Ellestad GA, Reddy P, Wolfson MF, Rauch CT, Castner BJ, Davis R, Clarke HR, Petersen M, Fitzner JN, Cerretti DP, March CJ, Paxton RJ, Black RA, Bode W: Crystal structure of the catalytic domain of human tumor necrosis factor-a-converting enzyme. Proc Natl Acad Sei USA (1998) 95:3408-3412. The first crystal structure of an ADAM gene family member. There will be considerable use of structure-based studies in the design of inhibitors of ADAM and ADAM-TS gene family members.
-
(1998)
Proc Natl Acad Sei USA
, vol.95
-
-
Maskos, K.1
|